This study aims at investigating
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At 2300 h, plasma 3-OH-butyrate levels were similar in the three groups (around 150 pmol/L (J Clin Endocrinol Metab 81: 1975 -1978 , 1996 I NTENSIVE insulin therapy and improved metabolic control effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with insulin-dependent diabetes mellitus (1). Intensive insulin therapy is composed of an entire therapeutic program of diabetes management, one component of which is optimized insulin administration (2). Continuous SC insulin infusion (CSII) is a precise way to mimic clinically the physiology of daily insulin secretion (2,3). In insulin-dependent diabetic patients, long-term maintenance of satisfactory metabolic control is attainable with CSII, although this is mainly dependent upon patient concern and motivation (4). Interruption of insulin infusion is a cause of concern when using CSII, particularly during the nighttime (5-7). The interruption can be intentional (in order to allow certain activities) or unintentional: catheter occlusion, often caused by improper insulin preparations (81, catheter disinsertion, battery failure, insulin exhaustion, etc. The inadvertent or the intentional interruptions of insulin infusion may be in part responsible for the development of ketoacidotic episodes in CSII-treated diabetic patients (7).
The metabolic control at the time of CSII interruption may affect the subsequent metabolic evolution. Elucidation of this point is important in order to advise CSII-treated patients concerning a possible CSII interruption. This study shows the influence of the prevailing blood glucose (BG) level, i.e. hypo-, normo-, or hyperglycemia, on the metabolic deterioration that follows a 6-h nocturnal intentional interruption of CSII in type-l C-peptide negative diabetic patients.
Patients

Materials and Methods
Fifteen type 1, C-peptide negative, diabetic patients currently treated with CSII uarticiuated in the studv. All gave their free and fullv informed 
Experimental procedure
All subjects were submitted to the same experimental procedure, which consisted of interrupting the CSII from 2300 h until 0500 h the next day. A detailed description of this approach has been previously reported (9). Venous blood was collected hourly from 2200 h to 0600 h, and plasma-free insulin, BG, plasma 3-hydroxybutyrate, free fatty acid (FFA), glycerol, glucagon, and GH were measured using the methods previously referenced (9, 10). 
Statistical analysis
When comparing the three groups of patients, statistical evaluation was performed by ANOVA followed by the Newman-Keuls-Heartly test. Within each group, the Student's t test for paired data was used for comparison US. the value recorded at 2300 h, considered as baseline. The individual Newman-Keuls-Heartly or t tests were considered significant only if overall significance was established by ANOVA. Results are expressed as mean -C SEM.
Plasma-free insulin Results
Before CSII interruption, plasma-free insulin levels did not differ significantly between the three groups of patients, although the mean values tended (P < 0.1) to be higher in the hypoglycemic group and lower in the hyperglycemic group (Fig. 1) . After CSII interruption, a similar abrupt decrease was observed in the three groups (ANOVA tests, P < 0.004). At the end of the interruption period, free insulin levels were similarly low. BG Mean (*SEMI BG levels at the time of CSII interruption were 11.2 -+ 1.0, 6.2 ? 0.7, and 1.9 2 0.1 mmol/L in hyper-, normo-, and hypoglycemic patients, respectively. Significant increases in BG levels were observed 3 h after the interruption in hyper-and hypoglycemic but not in normoglycemic patients (Fig. 1) . BG levels were at any time point much higher in the initially hyperglycemic patients (ANOVA test, P < 0.01). Indeed, at the end of the interruption period, BG levels were 19.4 2 1.2,14.1 t 1.2, and 13.5 2 1.3 mmol/L for hyper-, normo-, and hypoglycemic patients, respectively. The increments in BG levels over baseline values were significantly (P < 0.02) greater in the hypo-(11.6 +-1.3 mmol/L) than in the hyper-(8.1 t 0.5 mmol/L) or normo-(8.0 + 0.5 mmol/L) glycemic group.
Plasma 3-OH-butyrate
Before the CSII interruption, plasma 3-OH-butyrate levels were similar in the three groups, around 150 pmol/L. As a consequence of CSII interruption, 3-OH-butyrate levels significantly increased (ANOVA tests, P < O.OOl), although initially more slowly in the normoglycemic and more rapidly in the other two groups (Fig. 1) . The rate of increase was greater in hyper-than in normo-or hypoglycemic patients. At the end of the interruption period, the respective 3-OHbutyrate levels were 1460 5 127, 868 -+ 150, and 837 t 80 pmol/L (ANOVA test, P < 0.01).
Plasma FFA and glycerol Before CSII interruption, FFA levels were already much higher in the hyperglycemic group (723 + 62 pmol/L) than in the normo-(383 IT 76 pmol/L) or hypoglycemic (363 +-113 pmol/L) groups (ANOVA test, P < 0.02). After CSII interruption, the specific response was somewhat different in the three groups (Fig. 2) . In normoglycemic patients, plasma levels tended (ANOVA test, P = 0.09) to increase only at the end of the interruption period. In hypoglycemic patients, a statistically significant (ANOVA test, P < 0.01) rise was already observed after 2 h of CSII interruption. In hyperglycemic patients, plasma FFA levels increased (ANOVA test, P < 0.005) during the whole period of observation and were systematically higher in this than in the other two groups (ANOVA test, P < 0.05). Final values were 973 2 113 pmol/L in the hyper-, 670 +-126 pmol/L in the normo-and 552 t 19 pmol/L in the hypoglycemic group, respectively (ANOVA test, P < 0.03). The increase in plasma glycerol levels along the interruption period was not statistically significant, and there were no differences between the three groups of subjects (Fig. 2) .
Plasma glucagon and GH
From 2200-2300 h, i.e. before the interruption, plasma glucagon levels tended to decrease in normo-and hyperglycemic patients, whereas they were somewhat higher and tended to further increase in hypoglycemic patients (Fig. 3) . At the end of the interruption period, plasma glucagon levels tended to increase in all the groups, although these variations were not statistically significant after ANOVA. GH levels peaked several times during the first part of the nocturnal sleep in the three groups of patients. Hypoglycemic patients presented initial higher levels (ANOVA test, P < 0.02), and the peak was of greater amplitude (Fig. 3) .
Discussion
Adequate overnight metabolic control is attainable with CSII, but a nocturnal interruption of the SC infusion results in a rapid and sustained metabolic deterioration (7, 9, 10). The extent to which BG control at the time of the interruption influences the subsequent metabolic deterioration had not been investigated until now. Our results show that the degree of metabolic control at the time of the interruption is an important determinant of the subsequent evolution.
The metabolic deterioration that follows CSII interruption is primarily the result of a rapid fall in free insulin circulating levels (9,ll). This may be beneficial in cases of hypoglycemia but also increases the risk of rapidly developing hyperglycemia and ketoacidosis (7). The rapid (1 h) decrease in plasma free insulin levels contrasts with the slow BG response to CSII interruption (12,13). This time lag between the changes in BG and free insulin levels may reflect the time lag existing between the changes in insulin concentration in the plasma compartment and in the remote active compartment of insulin, where the hormone is actually physiologically active (14). In addition, for normoglycemic patients, the relatively higher peripheral insulin levels together with lower counterregulatory hormones may retard the rise in plasma glucose (15).
The magnitude of the BG rise is higher for initially hypoglycemic than for hyper-or normoglycemic patients. This can be explained by the initiation of a counterregulatory response. As recently described, with meticulous prevention of hypoglycemia, intensive insulin therapy decreases rather than increases the risk of hypoglycemia by improving the counterregulatory hormonal response (particularly of GH, glucagon, and cortisol) and determining a more efficient are as shown in Fig. 1. of the CSII interruption, probably because of the presence of massive glycosuria, which compensates for the increased hepatic glucose production. Following CSII interruption, the increase in plasma FFA and 3-OH-butyrate levels occurs at an early stage and at a faster pace than the increase in BG levels. The increased lipolysis and ketogenesis is a consequence of both the decrease in plasma-free insulin levels and the increase in glucagon (17-19). However, the initial metabolic state plays an important role. In the initially hyperglycemic patients, higher FFA levels at baseline may indicate an enhanced lipolytic state that is aggravated by the decrease in insulin after CSII interruption. At baseline, the higher FFA and similar normal 3-OH-butyrate in hyperglycemic patients is intriguing. The inhibition of ketogenesis by even small amounts of insulin can partly explain this fact. After CSII interruption, the higher plasma 3-OH-butyrate levels in hyperglycemic patients probably reflect higher FFA availability because no other difference in terms of insulin or counterregulatory hormones, particularly glucagon, was noticed. In initially hypoglycemic patients, the early increases in plasma FFA and 3-OH-butyrate levels can be explained by the stimulatory effect of counterregulatory hormones (17-19). In conclusion, a 6-hour nocturnal interruption of a CSII induces a serious metabolic deterioration in insulin-dependent, C-peptide negative, diabetic patients. This metabolic deterioration is, however, markedly affected by the metabolic situation at the time of the interruption.
In hypoglycemic patients, the metabolic deterioration initially proceeds at a faster pace but ends similarly to the situation observed in initially normoglycemic subjects. In initially hyperglycemic patients, a greater metabolic deterioration is observed. Thus, in all situations of hyperglycemia, CSII-treated patients should pay special attention to their infusion devices to avoid an inadvertent interruption or leakage of the insulin infusion that may result in the rapid development of ketoacidosis, especially during the night. 
